Seattle Genetics Gets Fast Track

Luke Timmerman3/30/09

Seattle Genetics, the Bothell, WA-based cancer drug developer, said today it has received “Fast Track” designation from the FDA for the pivotal trial of its SGN-35 drug for Hodgkin’s disease. The designation, which the FDA provides to potentially life-saving therapies, will allow Seattle Genetics (NASDAQ: SGEN) to submit data in its application on a rolling basis as it becomes available. The company still hopes to turn in its application to the FDA in 2011, although it has potential for an expedited six-month regulatory review instead of the usual 10 months.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.